论文部分内容阅读
目的探讨肿瘤疫苗在临床应用效果,分析有效成分,为进一步纯化肿瘤疫苗打下良好基础。方法提取肺部肿瘤临床标本的可溶性抗原,和金葡菌超抗原等共同构建肿瘤疫苗,对112例肺癌术后患者(治疗组56例,对照组56例),经3～10年随访,观察临床效果;分离提取肿瘤标本中的膜蛋白、DNA、RNA、HSP70以及多肽,分析其有效成分。结果治疗组患者5年生存率高于对照组,其差异有统计学意义(P<0.01);治疗组患者未见全身及局部明显毒副作用;该疫苗的主要有效成分是多肽,膜蛋白也具有免疫活性。结论用该方法构建的肿瘤疫苗用于肺癌术后患者可提高5年生存率,患者耐受性好;该疫苗的主要有效成分是多肽和膜抗原。
Objective To investigate the effect of tumor vaccine in clinical application, analyze the active ingredients, and lay a good foundation for further purification of tumor vaccine. Methods The soluble antigens of clinical specimens of lung cancer were extracted and combined with S. aureus superantigens to construct tumor vaccines. After 112 patients with lung cancer (56 in treatment group and 56 in control group), the patients were followed up for 3 to 10 years Clinical effect; separation and extraction of tumor samples of membrane protein, DNA, RNA, HSP70 and peptides, analysis of its active ingredients. Results The 5-year survival rate of the treatment group was significantly higher than that of the control group (P <0.01). The systemic and local toxicities and side effects were not observed in the treatment group. The main active ingredient of the vaccine was the polypeptide, and the membrane protein also had Immune activity. Conclusions The tumor vaccine constructed by this method can improve the 5-year survival rate of patients with lung cancer and the patient’s tolerance is good. The main active ingredients of the vaccine are polypeptides and membrane antigens.